Sugemalimab

L01FF11(WHO) UK:POM(Prescription only)EU:Rx-onlyIn general: ℞ (Prescription only) 2256084-03-2 DB16641 90IQR2I6TR D12750 Sugemalimab, sold under the brand nameCejemlyamong others, is amonoclonal antibodyused for the treatment of metastaticnon-small cell lung cancer(NSCLC) in combination with chemotherapy.It is an antineoplastic monoclonal antibody that potentiates T-cell responses, including anti-tumor responses, through blockade of PD-1 binding to PD-L1 ligands. The most common side effects include anemia (low red blood cells), increased levels ofaminotransferases(liver enzymes),rash,hyperlipidemia(high blood fat levels),hyperglycemia(high blood glucose levels),hyponatremia(low blood levels of sodium),hypokalemia(low blood levels of potassium),proteinuria(protein in urine), abdominal (belly) pain,tiredness,arthralgia(joint pain),hypoesthesia(reduced sensation to touch, pain and temperature),hypothyroidism(underactive thyroid gland) andhypocalcemia(low blood levels of calcium). Sugemalimab was approved for medical use in China in December 2021,the European Union in July 2024,and the United Kingdom in October 2024.